XNAS
PYPD
Market cap28mUSD
May 30, Last price
2.80USD
1D
0.36%
1Q
-13.31%
IPO
-99.51%
Name
PolyPid Ltd
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
25.94%
Rev. gr., 5y
%
Revenues
0k
Net income
-24m
L-39.62%
CFO
-22m
L+27.43%
Earnings
Aug 12, 2025
Profile
PolyPid Ltd., a late-stage biopharma company, develops, manufactures, and commercializes products based on polymer-lipid encapsulation matrix (PLEX) platform to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in Phase III clinical trial for the prevention of sternal (bone) surgical site infections (SSIs), as well as for the prevention of abdominal (soft tissue) SSIs. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | 17,970 | 40,609 | ||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | (17,970) | (40,609) | ||||||||
NOPBT Margin | ||||||||||
Operating Taxes | 69 | 97 | ||||||||
Tax Rate | ||||||||||
NOPAT | (18,039) | (40,706) | ||||||||
Net income | (23,865) -39.62% | (39,525) -2.92% | ||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | 35,863 | 8,723 | 4,423 | |||||||
BB yield | -163.46% | -32.64% | ||||||||
| Debt | ||||||||||
Debt current | 7,706 | 4,543 | 4,983 | |||||||
Long-term debt | 4,107 | 8,633 | 10,879 | |||||||
Deferred revenue | 2,548 | 2,548 | 2,548 | |||||||
Other long-term liabilities | 396 | 398 | 174 | |||||||
Net debt | (3,828) | 7,567 | 3,268 | |||||||
| Cash flow | ||||||||||
Cash from operating activities | (21,963) | (17,236) | (34,317) | |||||||
CAPEX | (76) | (196) | (1,767) | |||||||
Cash from investing activities | (330) | 3,804 | 16,575 | |||||||
Cash from financing activities | 32,416 | 9,976 | 16,428 | |||||||
FCF | 848 | (15,579) | (43,623) | |||||||
| Balance | ||||||||||
Cash | 15,641 | 5,609 | 12,594 | |||||||
Long term investments | ||||||||||
Excess cash | 15,641 | 5,609 | 12,594 | |||||||
Stockholders' equity | (267,331) | (238,309) | (214,412) | |||||||
Invested Capital | 287,576 | 250,938 | 236,717 | |||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | 1,404 | 648 | ||||||||
Price | 3.04 -20.00% | 3.80 -81.84% | 20.93 -87.85% | |||||||
Market cap | 5,337 -60.62% | 13,550 -87.39% | ||||||||
EV | 12,904 | 16,818 | ||||||||
EBITDA | 1,622 | (16,148) | (38,888) | |||||||
EV/EBITDA | ||||||||||
Interest | 1,711 | 1,023 | ||||||||
Interest/NOPBT | ||||||||||